Related Experiment Video
Updated: Jan 30, 2026

Gene-targeted Random Mutagenesis to Select Heterochromatin-destabilizing Proteasome Mutants in Fission Yeast
Published on: May 15, 2018
Proof of an Outer Membrane Target of the Efflux Inhibitor Phe-Arg-β-Naphthylamide from Random Mutagenesis
Sabine Schuster1, Jürgen A Bohnert2, Martina Vavra3
1Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, 79106 Freiburg, Germany. sabine.schuster@uniklinik-freiburg.de.
Abstract:
Phe-Arg-β-naphthylamide (PAβN) has been characterized as an efflux pump inhibitor (EPI) acting on the major multidrug resistance efflux transporters of Gram-negative bacteria, such as AcrB in Eschericha coli. In the present study, in vitro random mutagenesis was used to evolve resistance to the sensitizing activity of PAβN with the aim of elucidating its mechanism of action. A strain was obtained that was phenotypically similar to a previously reported mutant from a serial selection approach that had no efflux-associated mutations. We could confirm that acrB mutations in the new mutant were unrelated to PAβN resistance. The next-generation sequencing of the two mutants revealed loss-of-function mutations in lpxM. An engineered lpxM knockout strain showed up to 16-fold decreased PAβN activity with large lipophilic drugs, while its efflux capacity, as well as the efficacy of other EPIs, remained unchanged. LpxM is responsible for the last acylation step in lipopolysaccharide (LPS) synthesis, and lpxM deficiency has been shown to result in penta-acylated instead of hexa-acylated lipid A. Modeling the two lipid A types revealed steric conformational changes due to underacylation. The findings provide evidence of a target site of PAβN in the LPS layer, and prove membrane activity contributing to its drug-sensitizing potency.
Insights
Phe-Arg-β-naphthylamide (PAβN) resistance arises from mutations in the lpxM gene, not efflux pumps. This indicates PAβN targets the lipopolysaccharide (LPS) layer in bacteria.
Area of Science:
- Microbiology
- Bacterial Physiology
- Drug Resistance
Background:
- Phe-Arg-β-naphthylamide (PAβN) is known as an efflux pump inhibitor (EPI) targeting major multidrug resistance transporters like AcrB in Gram-negative bacteria.
- Understanding PAβN's mechanism of action is crucial for developing strategies to combat bacterial multidrug resistance.
Purpose of the Study:
- To elucidate the mechanism of action of Phe-Arg-β-naphthylamide (PAβN).
- To identify the molecular targets responsible for PAβN resistance and sensitizing activity.
Main Methods:
- In vitro random mutagenesis was employed to evolve bacterial resistance to PAβN.
- Next-generation sequencing was used to identify mutations in resistant strains.
- An engineered lpxM knockout strain was created to assess the role of LpxM in PAβN activity.
- Molecular modeling was used to analyze structural changes in lipid A.
Main Results:
- Mutations conferring PAβN resistance were found in the lpxM gene, not in efflux pump genes like acrB.
- lpxM deficiency resulted in significantly decreased PAβN activity (up to 16-fold) against large lipophilic drugs.
- The efflux capacity and efficacy of other EPIs remained unaffected in lpxM mutants.
- lpxM deficiency leads to underacylated lipid A, causing steric conformational changes in the bacterial membrane.
Conclusions:
- PAβN's target is located in the lipopolysaccharide (LPS) layer, specifically involving lipid A structure.
- The drug-sensitizing potency of PAβN is linked to its interaction with the bacterial membrane and LPS.
- PAβN resistance can arise from alterations in LPS synthesis, independent of efflux pump activity.
Related Concept Videos
Social Proof
Porin Insertion in the Outer Mitochondrial Membrane
Three models describe the assembly of porins by the SAM complex and their insertion into the outer membrane. Model 1 suggests that porins are assembled outside the SAM channel as the...
Protein Transport to the Outer Chloroplast Membrane
Two models describe the mechanism of precursor recognition and entry across the outer membrane through the TOC complex. Model 1 suggests the newly synthesized precursor binds to the TOC receptor 159 and forms a complex.
In-vitro Mutagenesis
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Random Error

